Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Robert Hariri
AddedMar 31, 2024
UpdatedJun 28, 2026
Robert Hariri

Robert Hariri

Co-Founder, Celgene

Crunchbase

Robert Hariri's Career

Celgene
Celgene

Summit, NJ, US

Co-Founder
Celularity
Celularity

Florham Park, NJ, US

Board Member· Board
Human Longevity
Human Longevity

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Robert Hariri's Career

Celgene
Celgene
Acquired01986Summit, NJ, US
Co-Founder

Leadership at Celgene

Ernie MarioErnie MarioBoard Member
Michael CaseyMichael CaseyBoard Member
Sol J. BarerSol J. BarerBoard Member
P Joseph CampisiP Joseph CampisiBoard Member
Jacqualyn FouseJacqualyn FouseBoard Member
Robert HuginRobert HuginBoard Member
Celularity
Celularity
Public$400M2252016Florham Park, NJ, US
Board Member· Board

Leadership at Celularity

Jaisim ShahJaisim ShahBoard Member
Jodi GurneyJodi GurneyCo-Founder
Carlos RamirezCarlos RamirezCo-Founder
Dean KehlerDean KehlerBoard Member
Peter DiamandisPeter DiamandisBoard Member
JOHN HAINESJOHN HAINESCo-Founder

Similar to Celularity

Platelet BioGenesisPlatelet BioGenesisWatertown, MA, USCell Therapyest. 2014Platelet BioGenesisWatertown, MA, US · est. 2014

US-based PlateletBio pioneers in allogeneic cell therapy, innovating superior solutions for unmet medical challenges.

Series B · $132.1M39
Cell BioEnginesCell BioEnginesNew York City, NY, USCell Therapiesest. 2022Cell BioEnginesNew York City, NY, US · est. 2022

Cell BioEngines, Inc.: A clinical-stage biotech firm innovating cancer cures with scalable cell therapies.

Pre-Seed · $625k6
Cellular ApproachesCellular ApproachesLos Angeles, CA, USCell Therapiesest. 2016Cellular ApproachesLos Angeles, CA, US · est. 2016

Cellular Approaches: Innovating in innate immunity biotech for unmet medical needs.

Seed · $2.6M5
HebeCellHebeCellNatick, MA, USCell Therapiesest. 2016HebeCellNatick, MA, US · est. 2016

MA-based HebeCell pioneers in immuno-oncology and regenerative medicine through cell-based therapeutics.

Series A · $63M24
Human Longevity
Human Longevity

San Diego, CA, US

Board Member· Board

Robert Hariri's Co-Investors

Jay sethuramJay sethuramCo-invested · Moon Express Series UnknownRob NailRob NailCo-invested · Moon Express Series UnknownRiz VirkRiz VirkCo-invested · Moon Express Series UnknownPeter FarrellPeter FarrellCo-invested · Moon Express Series UnknownPaul GauthierPaul GauthierCo-invested · Moon Express Series UnknownNaveen JainNaveen JainCo-invested · Moon Express Series UnknownRichard MerkinRichard MerkinCo-invested · Moon Express Series UnknownKlee IrwinKlee IrwinCo-invested · Moon Express Series Unknown

Robert Hariri's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Robert Hariri

Robert Hariri GordonRobert Hariri GordonBoard Member · CelularityRobert J. HarmanRobert J. HarmanFounder · Personalized Stem CellsJay BloomJay BloomBoard Member · CelularityGeert R. KerstenGeert R. KerstenBoard Member · Cel-SciDrew SenyeiDrew SenyeiBoard Member · Celula